Pharma Likelihood Of Approval
We are the trusted, gold standard intelligence provider to the world’s largest industries
GlobalData powers faster, more informed decisions with:
- Granular industry intelligence: We develop deep, vertical-specific intelligence tailored to your industry, providing 360° insight.​
- Exhaustive coverage: We synthesize our vast data universe into formats that support your decision-making needs, covering the sectors, themes, companies and geographies that matter to you. ​
- Proprietary datasets: We provide you with access to untapped pools of intelligence generated from our proprietary datasets and primary research capabilities. ​
- Robust methodologies: The quality and timeliness of our data is a key differentiator. We leverage robust research methodologies to turn millions of data points into trusted intelligence.
Thousands of companies, government organizations, and decision makers rely on GlobalData
We have a track record of serving truly diverse clients, including:
- Corporates: From helping the C-suite refine strategy to powering innovation in marketing and R&D, our corporate use cases are endless. ​
- Investment firms: We help financial analysts develop robust long-term strategies and get alpha signals before the rest. ​
- Professional services: We give consultants, legal, and accounting firms the critical insights to make faster, more informed decisions. ​
- Other sectors: From media to academia, we work with sectors as diverse as our data. ​
The trusted, actionable and future-proof insight you need to stay ahead
We have decades of experience in being the gold standard intelligence provider based on: ​
- Unique data: Proprietary datasets built from terabytes of data. Our unmatched intelligence gives you true strategic advantage.
- Expert analysis: Leverage collective expertise. Count on our extensive team of researchers, analysts, subject matter experts, and journalists, plus thousands of external thought-leaders.​
- Real intelligence over AI: Experience a level of analysis that leaves AI in the dust. Unlock the proprietary datasets unseen by AI and gain a decisive edge. ​
- Time-saving research solutions: Save hundreds of hours on research. Our comprehensive reports let you focus on delivering actionable insights - not searching for them. ​
- Unparalleled global coverage: Tap into insights from anywhere. Our extensive global coverage offers an unrivalled view of the market landscape.​
- One platform: Access all our unique data, expert analysis, and innovative solutions on one platform. ​
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Istaroxime in Cardiogenic Shock
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Istaroxime in Cardiogenic Shock report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Istaroxime in Cardiogenic ShockDrug Details:Istaroxime (Debio-0614, PST-2744) is under development for the acute...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Thrombomodulin Alfa in Chemotherapy Induced Peripheral Neuropathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Thrombomodulin Alfa in Chemotherapy Induced Peripheral Neuropathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Thrombomodulin Alfa in Chemotherapy Induced Peripheral NeuropathyDrug Details:Thrombomodulin alpha (Recomodulin)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Sparsentan in Focal Segmental Glomerulosclerosis (FSGS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sparsentan in Focal Segmental Glomerulosclerosis (FSGS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sparsentan in Focal Segmental Glomerulosclerosis (FSGS) Drug Details: Sparsentan...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Avacincaptad Pegol Sodium in Juvenile Macular Degeneration (Stargardt Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Avacincaptad Pegol Sodium in Juvenile Macular Degeneration (Stargardt Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Avacincaptad Pegol Sodium in Juvenile Macular Degeneration (Stargardt...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Panobacumab in Pseudomonas aeruginosa Pneumonia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Panobacumab in Pseudomonas aeruginosa Pneumonia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Panobacumab in Pseudomonas aeruginosa Pneumonia Drug Details: AR-101 (panobacumab, KBPA101)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Melphalan in Primary Systemic Amyloidosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Melphalan in Primary Systemic Amyloidosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Melphalan in Primary Systemic AmyloidosisDrug Details:Melphalan (Evomela) is a phenylpropanoic acid derivative,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Catequentinib Hydrochloride in Nasopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Catequentinib Hydrochloride in Nasopharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Catequentinib Hydrochloride in Nasopharyngeal Cancer Drug Details: Catequentinib hydrochloride (AL-3818) (Focus...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - LAT-8881 in Radiculopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LAT-8881 in Radiculopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.LAT-8881 in RadiculopathyDrug Details:LAT-8881 is under development for the treatment of migraine. The drug...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Vidutolimod in Laryngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vidutolimod in Laryngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vidutolimod in Laryngeal Cancer Drug Details: CMP-001 (CYT-003) is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Vidutolimod in Oral Cavity (Mouth) Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vidutolimod in Oral Cavity (Mouth) Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vidutolimod in Oral Cavity (Mouth) Cancer Drug Details: CMP-001 (CYT-003)...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.